Which has stronger valuation & earnings, PEPG or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is PEPG or AURA more profitable?

PepGen's return on equity of -51.01% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Aura Biosciences N/A -73.18% -62.00%

Which has better earnings and valuation, PEPG or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is PEPG or CLYM more profitable?

Climb Bio's return on equity of -31.79% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Climb Bio N/A -31.79% -30.79%

PepGen (PEPG) Competitors

$2.28 +0.07 (+3.17%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.26 -0.02 (-0.88%)

As of 10/2/2026 07:30 PM Eastern

Compare

PEPG vs. AURA, CLYM, ACRS, IRWD, and CTMX

Should you buy PepGen stock or one of its competitors? PepGen's main competitors and comparable companies include Aura Biosciences (AURA), Climb Bio (CLYM), Aclaris Therapeutics (ACRS), Ironwood Pharmaceuticals (IRWD), and CytomX Therapeutics (CTMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PepGen compare to Aura Biosciences?

PepGen (NASDAQ:PEPG) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, PepGen's average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.

Company	Overall Sentiment
PepGen	Neutral
Aura Biosciences	Neutral

PepGen's return on equity of -51.01% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Aura Biosciences	N/A	-73.18%	-62.00%

Aura Biosciences is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

PepGen currently has a consensus target price of $11.40, suggesting a potential upside of 400.00%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 187.36%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts clearly believe PepGen is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

58.0% of PepGen shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PepGen has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Summary

PepGen beats Aura Biosciences on 9 of the 11 factors compared between the two stocks.

How does PepGen compare to Climb Bio?

PepGen (NASDAQ:PEPG) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

PepGen presently has a consensus price target of $11.40, suggesting a potential upside of 400.00%. Climb Bio has a consensus price target of $26.92, suggesting a potential upside of 146.10%. Given PepGen's higher possible upside, equities research analysts plainly believe PepGen is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

58.0% of PepGen shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Climb Bio had 4 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Climb Bio and 0 mentions for PepGen. Climb Bio's average media sentiment score of 0.59 beat PepGen's score of 0.00 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Climb Bio	Positive

PepGen has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Climb Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Climb Bio's return on equity of -31.79% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Climb Bio	N/A	-31.79%	-30.79%

Summary

Climb Bio beats PepGen on 11 of the 14 factors compared between the two stocks.

How does PepGen compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Aclaris Therapeutics has higher revenue and earnings than PepGen. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	78.39	-$64.92M	-$0.58	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Aclaris Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, PepGen has a beta of 2.01, suggesting that its stock price is 101% more volatile than the broader market.

Aclaris Therapeutics currently has a consensus price target of $11.33, suggesting a potential upside of 158.16%. PepGen has a consensus price target of $11.40, suggesting a potential upside of 400.00%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Aclaris Therapeutics had 6 more articles in the media than PepGen. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 0 mentions for PepGen. Aclaris Therapeutics' average media sentiment score of 0.19 beat PepGen's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Neutral
PepGen	Neutral

PepGen has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. PepGen's return on equity of -51.01% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
PepGen	N/A	-51.01%	-43.49%

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 1.3% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats PepGen on 10 of the 15 factors compared between the two stocks.

How does PepGen compare to Ironwood Pharmaceuticals?

PepGen (NASDAQ:PEPG) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Ironwood Pharmaceuticals has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.77	4.73

PepGen presently has a consensus target price of $11.40, suggesting a potential upside of 400.00%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 71.25%. Given PepGen's stronger consensus rating and higher possible upside, research analysts clearly believe PepGen is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

PepGen has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

58.0% of PepGen shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than PepGen. MarketBeat recorded 1 mentions for Ironwood Pharmaceuticals and 0 mentions for PepGen. Ironwood Pharmaceuticals' average media sentiment score of 0.74 beat PepGen's score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Ironwood Pharmaceuticals	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to PepGen's net margin of 0.00%. PepGen's return on equity of -51.01% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats PepGen on 10 of the 16 factors compared between the two stocks.

How does PepGen compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CytomX Therapeutics had 3 more articles in the media than PepGen. MarketBeat recorded 3 mentions for CytomX Therapeutics and 0 mentions for PepGen. CytomX Therapeutics' average media sentiment score of 0.14 beat PepGen's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Neutral
PepGen	Neutral

CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, PepGen has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market.

CytomX Therapeutics currently has a consensus price target of $11.90, indicating a potential upside of 364.84%. PepGen has a consensus price target of $11.40, indicating a potential upside of 400.00%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

PepGen has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
PepGen	N/A	-51.01%	-43.49%

CytomX Therapeutics has higher revenue and earnings than PepGen. CytomX Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.32	-$17.37M	-$0.50	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Summary

CytomX Therapeutics beats PepGen on 13 of the 16 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$157.91M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.74	13.00	274.71	26.04
Price / Sales	N/A	1,288.64	656.46	105.16
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.07	16.57	10.93	6.31
Net Income	-$89.65M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-11.97%	-2.97%	-2.00%	-1.66%
1 Month Performance	-26.69%	-10.82%	-6.19%	-4.68%
1 Year Performance	-55.56%	19.00%	8.03%	1.57%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	1.333 of 5 stars	$2.28 +3.2%	$11.40 +400.0%	-55.6%	$157.91M	N/A	N/A	57	Positive News
AURA Aura Biosciences	1.2953 of 5 stars	$6.08 +0.6%	$17.50 +188.1%	+0.7%	$630.04M	N/A	N/A	113	News Coverage
CLYM Climb Bio	2.6604 of 5 stars	$10.84 -2.1%	$26.92 +148.4%	+452.5%	$622.42M	N/A	N/A	29	News Coverage Analyst Downgrade
ACRS Aclaris Therapeutics	2.0953 of 5 stars	$4.34 -1.6%	$11.33 +161.1%	+136.0%	$606.12M	$7.83M	N/A	73	Positive News Analyst Downgrade
IRWD Ironwood Pharmaceuticals	2.3837 of 5 stars	$3.65 -3.1%	$6.23 +71.0%	+134.8%	$602.30M	$296.15M	4.73	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. AURA, CLYM, ACRS, IRWD, and CTMX

How does PepGen compare to Aura Biosciences?

Summary

How does PepGen compare to Climb Bio?

Summary

How does PepGen compare to Aclaris Therapeutics?

Summary

How does PepGen compare to Ironwood Pharmaceuticals?

Summary

How does PepGen compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. AURA, CLYM, ACRS, IRWD, and CTMX

How does PepGen compare to Aura Biosciences?

Does the media refer more to PEPG or AURA?

Is PEPG or AURA more profitable?

Which has stronger valuation & earnings, PEPG or AURA?

Do analysts rate PEPG or AURA?

Do institutionals and insiders have more ownership in PEPG or AURA?

Which has more volatility and risk, PEPG or AURA?

Summary

How does PepGen compare to Climb Bio?

Do analysts rate PEPG or CLYM?

Do institutionals & insiders have more ownership in PEPG or CLYM?

Does the media refer more to PEPG or CLYM?

Which has more risk & volatility, PEPG or CLYM?

Which has better earnings and valuation, PEPG or CLYM?

Is PEPG or CLYM more profitable?

Summary

How does PepGen compare to Aclaris Therapeutics?

Which has better valuation & earnings, ACRS or PEPG?

Which has more risk and volatility, ACRS or PEPG?

Do analysts rate ACRS or PEPG?

Does the media favor ACRS or PEPG?

Is ACRS or PEPG more profitable?

Do insiders and institutionals hold more shares of ACRS or PEPG?

Summary

How does PepGen compare to Ironwood Pharmaceuticals?

Which has preferable earnings and valuation, PEPG or IRWD?

Do analysts recommend PEPG or IRWD?

Which has more risk & volatility, PEPG or IRWD?

Do institutionals & insiders hold more shares of PEPG or IRWD?

Does the media favor PEPG or IRWD?

Is PEPG or IRWD more profitable?

Summary

How does PepGen compare to CytomX Therapeutics?

Do insiders & institutionals believe in CTMX or PEPG?

Does the media prefer CTMX or PEPG?

Which has more volatility & risk, CTMX or PEPG?

Do analysts recommend CTMX or PEPG?

Is CTMX or PEPG more profitable?

Which has better earnings & valuation, CTMX or PEPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools